These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23512247)

  • 1. A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.
    Kümler I; Brünner N; Stenvang J; Balslev E; Nielsen DL
    Breast Cancer Res Treat; 2013 Apr; 138(2):347-58. PubMed ID: 23512247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.
    Holcombe RF; Kong KM; Wimmer D
    Anticancer Drugs; 2004 Jul; 15(6):569-74. PubMed ID: 15205598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
    Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
    Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.
    Kümler I; Balslev E; Stenvang J; Brünner N; Nielsen D
    BMC Cancer; 2015 Feb; 15():78. PubMed ID: 25885574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of weekly combined topotecan and irinotecan.
    Lokich J
    Am J Clin Oncol; 2001 Aug; 24(4):336-40. PubMed ID: 11474256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer.
    Segar JM; Reed D; Stopeck A; Livingston RB; Chalasani P
    Oncologist; 2019 Dec; 24(12):1512-e1267. PubMed ID: 31383812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.
    Perez EA; Hillman DW; Mailliard JA; Ingle JN; Ryan JM; Fitch TR; Rowland KM; Kardinal CG; Krook JE; Kugler JW; Dakhil SR
    J Clin Oncol; 2004 Jul; 22(14):2849-55. PubMed ID: 15254052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
    Awada A; Garcia AA; Chan S; Jerusalem GH; Coleman RE; Huizing MT; Mehdi A; O'Reilly SM; Hamm JT; Barrett-Lee PJ; Cocquyt V; Sideras K; Young DE; Zhao C; Chia YL; Hoch U; Hannah AL; Perez EA;
    Lancet Oncol; 2013 Nov; 14(12):1216-25. PubMed ID: 24095299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?
    Vasey PA; Kaye SB
    Br J Cancer; 1997; 76(11):1395-7. PubMed ID: 9400932
    [No Abstract]   [Full Text] [Related]  

  • 12. New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.
    Huang CH; Treat J
    Oncology; 2001; 61 Suppl 1():14-24. PubMed ID: 11598410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
    Bonneterre J
    Bull Cancer; 1995 Aug; 82(8):623-8. PubMed ID: 7492818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
    Kantarjian HM; Beran M; Ellis A; Zwelling L; O'Brien S; Cazenave L; Koller C; Rios MB; Plunkett W; Keating MJ
    Blood; 1993 Mar; 81(5):1146-51. PubMed ID: 8382970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
    Slichenmyer WJ; Rowinsky EK; Grochow LB; Kaufmann SH; Donehower RC
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S53-7. PubMed ID: 7520844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck.
    Murphy BA
    Expert Opin Pharmacother; 2005 Jan; 6(1):85-92. PubMed ID: 15709886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
    Mrozek E; Kolesar J; Young D; Allen J; Villalona-Calero M; Shapiro CL
    Ann Oncol; 2008 Aug; 19(8):1417-1422. PubMed ID: 18407955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of topoisomerase I inhibitors in anticancer treatment.
    Rodriguez-Galindo C; Radomski K; Stewart CF; Furman W; Santana VM; Houghton PJ
    Med Pediatr Oncol; 2000 Oct; 35(4):385-402. PubMed ID: 11025469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
    Hayashi H; Tsurutani J; Satoh T; Masuda N; Okamoto W; Morinaga R; Terashima M; Miyazaki M; Okamoto I; Nishida Y; Tominaga S; Tokunaga Y; Yamaguchi M; Sakamoto J; Nakayama T; Nakagawa K
    Breast Cancer; 2013 Apr; 20(2):131-6. PubMed ID: 22124996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
    Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
    Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.